Key clinical point: Adding 2 years of ovarian function suppression to standard tamoxifen therapy could improve disease-free and overall survival in previously treated women with estrogen receptor–positive breast cancer.
Major finding: The 5-year estimated disease-free survival rate was 91.1% for patients who received tamoxifen and OFS, compared with 87.5% for those who received tamoxifen alone.
Study details: A phase 3, randomized trial involving 1,293 premenopausal women with estrogen receptor–positive breast cancer who were previously treated with chemotherapy and definitive surgery.
Disclosures: The study was primarily funded by AstraZeneca with additional support from the Korea Institute of Radiological and Medical Sciences. The investigators disclosed relationships with Novartis, Roche, Amgen, and others.
Kim HA et al. J Clin Oncol. 2019 Sep 16. doi: 10.1200/JCO.19.00126.